Cambridge Epigenetix Revenue and Competitors
Estimated Revenue & Valuation
- Cambridge Epigenetix's estimated annual revenue is currently $17.5M per year.
- Cambridge Epigenetix's estimated revenue per employee is $155,000
Employee Data
- Cambridge Epigenetix has 113 Employees.
- Cambridge Epigenetix grew their employee count by 23% last year.
Cambridge Epigenetix's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Research & Development | Reveal Email/Phone |
2 | Clinical Operations Consultant/Clinical Operations Lead | Reveal Email/Phone |
3 | Lab Tech | Reveal Email/Phone |
4 | Chair | Reveal Email/Phone |
Cambridge Epigenetix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $17.5M | 113 | 23% | N/A | N/A |
What Is Cambridge Epigenetix?
Cambridge Epigenetix aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification. We utilise innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com or email info@cambridge-epigenetix.com.
keywords:N/AN/A
Total Funding
113
Number of Employees
$17.5M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cambridge Epigenetix News
Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the ...
Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the ...
VC firm GV (née Google Ventures) has made another investment in Europe — its seventh — leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix. The U.K.-based bioscience company makes DNA modification analysis tools for ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 113 | 16% | N/A |
#2 | $17.5M | 113 | -18% | $233M |
#3 | $11.3M | 113 | 4% | N/A |
#4 | $20.5M | 114 | -1% | N/A |
#5 | $20.5M | 114 | 48% | N/A |